Drug intelligence / Profile preview

FORX-003

Development stage: Unknown
Lead developer: FoRx Therapeutics
Modality: Small Molecules

Overview

FORX-003 is a first-in-class drug candidate being developed by FoRx Therapeutics AG for the treatment of distinct types of cancer. It is designed to target DNA Replication Stress (DRS) pathways, representing a novel approach in the development of anticancer drugs. The program is currently in early Lead Identification, aiming to develop compounds for cancer types not yet addressed by other targeted DNA Damage Response (DDR) inhibitors.

Beyond the preview

Go deeper on FORX-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FORX-003.

Explore the full profile